135 related articles for article (PubMed ID: 18242992)
1. Discovery of novel FMS kinase inhibitors as anti-inflammatory agents.
Illig CR; Chen J; Wall MJ; Wilson KJ; Ballentine SK; Rudolph MJ; DesJarlais RL; Chen Y; Schubert C; Petrounia I; Crysler CS; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Meegalla SK
Bioorg Med Chem Lett; 2008 Mar; 18(5):1642-8. PubMed ID: 18242992
[TBL] [Abstract][Full Text] [Related]
2. Structure-based optimization of a potent class of arylamide FMS inhibitors.
Meegalla SK; Wall MJ; Chen J; Wilson KJ; Ballentine SK; Desjarlais RL; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Illig CR
Bioorg Med Chem Lett; 2008 Jun; 18(12):3632-7. PubMed ID: 18495479
[TBL] [Abstract][Full Text] [Related]
3. Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors.
Huang H; Hutta DA; Rinker JM; Hu H; Parsons WH; Schubert C; DesJarlais RL; Crysler CS; Chaikin MA; Donatelli RR; Chen Y; Cheng D; Zhou Z; Yurkow E; Manthey CL; Player MR
J Med Chem; 2009 Feb; 52(4):1081-99. PubMed ID: 19193011
[TBL] [Abstract][Full Text] [Related]
4. Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents.
Patch RJ; Brandt BM; Asgari D; Baindur N; Chadha NK; Georgiadis T; Cheung WS; Petrounia IP; Donatelli RR; Chaikin MA; Player MR
Bioorg Med Chem Lett; 2007 Nov; 17(22):6070-4. PubMed ID: 17904845
[TBL] [Abstract][Full Text] [Related]
5. Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).
Illig CR; Manthey CL; Wall MJ; Meegalla SK; Chen J; Wilson KJ; Ballentine SK; Desjarlais RL; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Donatelli RR; Yurkow E; Zhou Z; Player MR; Tomczuk BE
J Med Chem; 2011 Nov; 54(22):7860-83. PubMed ID: 22039836
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.
Illig CR; Manthey CL; Meegalla SK; Wall MJ; Chen J; Wilson KJ; DesJarlais RL; Ballentine SK; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Donatelli RR; Yurkow E; Zhou Z; Player MR; Tomczuk BE
Bioorg Med Chem Lett; 2013 Dec; 23(23):6363-9. PubMed ID: 24138939
[TBL] [Abstract][Full Text] [Related]
7. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
Wilson KJ; Illig CR; Chen J; Wall MJ; Ballentine SK; DesJarlais RL; Chen Y; Schubert C; Donatelli R; Petrounia I; Crysler CS; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Meegalla SK
Bioorg Med Chem Lett; 2010 Jul; 20(13):3925-9. PubMed ID: 20570147
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS.
Burns CJ; Harte MF; Bu X; Fantino E; Giarrusso M; Joffe M; Kurek M; Legge FS; Razzino P; Su S; Treutlein H; Wan SS; Zeng J; Wilks AF
Bioorg Med Chem Lett; 2009 Feb; 19(4):1206-9. PubMed ID: 19128971
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors.
Wall MJ; Chen J; Meegalla S; Ballentine SK; Wilson KJ; DesJarlais RL; Schubert C; Chaikin MA; Crysler C; Petrounia IP; Donatelli RR; Yurkow EJ; Boczon L; Mazzulla M; Player MR; Patch RJ; Manthey CL; Molloy C; Tomczuk B; Illig CR
Bioorg Med Chem Lett; 2008 Mar; 18(6):2097-102. PubMed ID: 18289848
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a new potent bisamide FMS kinase inhibitor.
El-Gamal MI; Jung MH; Oh CH
Bioorg Med Chem Lett; 2010 Jun; 20(11):3216-8. PubMed ID: 20457522
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel anilinoquinolines as c-fms inhibitors.
Smalley TL; Chamberlain SD; Mills WY; Musso DL; Randhawa SA; Ray JA; Samano V; Frick L
Bioorg Med Chem Lett; 2007 Nov; 17(22):6257-60. PubMed ID: 17870531
[TBL] [Abstract][Full Text] [Related]
12. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA
J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
[TBL] [Abstract][Full Text] [Related]
14. Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.
Mader M; de Dios A; Shih C; Bonjouklian R; Li T; White W; López de Uralde B; Sánchez-Martinez C; del Prado M; Jaramillo C; de Diego E; Martín Cabrejas LM; Dominguez C; Montero C; Shepherd T; Dally R; Toth JE; Chatterjee A; Pleite S; Blanco-Urgoiti J; Perez L; Barberis M; Lorite MJ; Jambrina E; Nevill CR; Lee PA; Schultz RC; Wolos JA; Li LC; Campbell RM; Anderson BD
Bioorg Med Chem Lett; 2008 Jan; 18(1):179-83. PubMed ID: 18039577
[TBL] [Abstract][Full Text] [Related]
15. The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors.
Neelamkavil SF; Boyle CD; Chackalamannil S; Greenlee WJ; Zhang L; Terracina G
Bioorg Med Chem Lett; 2009 Aug; 19(16):4563-5. PubMed ID: 19625185
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-inflammatory FMS inhibitors.
Huang H; Hutta DA; Hu H; DesJarlais RL; Schubert C; Petrounia IP; Chaikin MA; Manthey CL; Player MR
Bioorg Med Chem Lett; 2008 Apr; 18(7):2355-61. PubMed ID: 18342505
[TBL] [Abstract][Full Text] [Related]
17. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents.
Bürli RW; Xu H; Zou X; Muller K; Golden J; Frohn M; Adlam M; Plant MH; Wong M; McElvain M; Regal K; Viswanadhan VN; Tagari P; Hungate R
Bioorg Med Chem Lett; 2006 Jul; 16(14):3713-8. PubMed ID: 16697190
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
19. Toward the development of chemoprevention agents. Part 1: Design, synthesis, and anti-inflammatory activities of a new class of 2,5-disubstituted-dioxacycloalkanes.
Gu K; Bi L; Zhao M; Wang C; Ju J; Peng S
Bioorg Med Chem; 2007 Jul; 15(14):4775-99. PubMed ID: 17512740
[TBL] [Abstract][Full Text] [Related]
20. 3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor.
Scott DA; Dakin LA; Del Valle DJ; Diebold RB; Drew L; Gero TW; Ogoe CA; Omer CA; Repik G; Thakur K; Ye Q; Zheng X
Bioorg Med Chem Lett; 2011 Mar; 21(5):1382-4. PubMed ID: 21295474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
